Entry ID,Ligand,Value,Symbol,Type,Unit,PDB ID,Title,Structure Title,Stucture Keywords,Gene Name,EC Number,Annotation Identifier,Entity ID,Entry Id (Polymer Entity Identifiers),Target Protein,Accession Code(s),Database Name,Ligand Formula,Ligand MW,Ligand ID,Ligand Name,Ligand SMILES,Entity ID
7SXF,,,,,,7SXF,"Elucidation of the GSK3 alpha Structure Informs the Design of Novel, Paralog-Selective Inhibitors.",BIO-2895 (BRD0705) bound GSK3alpha-axin complex,HYDROLASE,GSK3A,"2.7.11.26, 2.7.11.1","GO:0097440, GO:0030424, GO:0030877, GO:0005737, GO:0005829, GO:0005874, GO:0005739, GO:0043025, GO:0005634, GO:0098794, GO:1990635, GO:0005524, GO:0034236, GO:0106310, GO:0004674, GO:0120283, GO:0005102, GO:0048156, GO:0050321, GO:0003214, GO:0016477, GO:0071385, GO:0032869, GO:0036016, GO:0071285, GO:0007212, GO:0060079, GO:0097191, GO:0097192, GO:0005977, GO:0008286, GO:0090090, GO:0061052, GO:2000171, GO:0044027, GO:0046325, GO:2000466, GO:0045719, GO:1904227, GO:0046627, GO:0032007, GO:2000077, GO:0010905, GO:0007399, GO:0018105, GO:0018107, GO:0071879, GO:0106071, GO:1902004, GO:0010508, GO:0010628, GO:2000467, GO:0045823, GO:1901030, GO:0043525, GO:0033138, GO:0010800, GO:0032436, GO:0045732, GO:1903955, GO:0031398, GO:0045944, GO:0043161, GO:0006468, GO:1903146, GO:0006349, GO:0010975, GO:0003073, GO:0019082, GO:0016055, IPR011009, IPR000719, IPR017441, IPR008271, IPR039192, P49840",1,7SXF,wildtype,P49840,UniProt,C20 H23 N3 O,321.416,6VL,"(4~{S})-4-ethyl-7,7-dimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one",CCC1(c2c[nH]nc2NC3=C1C(=O)CC(C3)(C)C)c4ccccc4,3
7SXG,,,,,,7SXG,"Elucidation of the GSK3 alpha Structure Informs the Design of Novel, Paralog-Selective Inhibitors.",BIO-8546 bound GSK3alpha-axin complex,HYDROLASE,GSK3A,"2.7.11.26, 2.7.11.1","GO:0097440, GO:0030424, GO:0030877, GO:0005737, GO:0005829, GO:0005874, GO:0005739, GO:0043025, GO:0005634, GO:0098794, GO:1990635, GO:0005524, GO:0034236, GO:0106310, GO:0004674, GO:0120283, GO:0005102, GO:0048156, GO:0050321, GO:0003214, GO:0016477, GO:0071385, GO:0032869, GO:0036016, GO:0071285, GO:0007212, GO:0060079, GO:0097191, GO:0097192, GO:0005977, GO:0008286, GO:0090090, GO:0061052, GO:2000171, GO:0044027, GO:0046325, GO:2000466, GO:0045719, GO:1904227, GO:0046627, GO:0032007, GO:2000077, GO:0010905, GO:0007399, GO:0018105, GO:0018107, GO:0071879, GO:0106071, GO:1902004, GO:0010508, GO:0010628, GO:2000467, GO:0045823, GO:1901030, GO:0043525, GO:0033138, GO:0010800, GO:0032436, GO:0045732, GO:1903955, GO:0031398, GO:0045944, GO:0043161, GO:0006468, GO:1903146, GO:0006349, GO:0010975, GO:0003073, GO:0019082, GO:0016055, IPR011009, IPR000719, IPR017441, IPR008271, IPR039192, P49840",1,7SXG,wildtype,P49840,UniProt,C26 H28 F2 N4 O2,466.523,D1E,"(4S,5R,8R)-4-ethyl-8-fluoro-4-[3-(3-fluoro-5-methoxypyridin-4-yl)phenyl]-7,7-dimethyl-4,5,6,7,8,9-hexahydro-2H-pyrazolo[3,4-b]quinolin-5-ol",CCC1(c2c[nH]nc2NC3=C1C(CC(C3F)(C)C)O)c4cccc(c4)c5c(cncc5F)OC,3
7X3J,,,,,,7X3J,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,Cryo-EM structure of human TRiC-tubulin-S2,STRUCTURAL PROTEIN,"TCP1, CCT1, CCTA",,"GO:0001669, GO:0044297, GO:0005813, GO:0005832, GO:0005829, GO:0070062, GO:0005794, GO:0000792, GO:0005874, GO:0000242, GO:0002199, GO:0005524, GO:0016887, GO:0140662, GO:0044183, GO:0003723, GO:0031625, GO:0051082, GO:0007339, GO:0061077, GO:1904851, GO:1904871, GO:0051973, GO:1904874, GO:0032212, GO:0006457, GO:0050821, GO:2000109, GO:0090666, GO:1901998, GO:0044053, GO:0007021, IPR012715, IPR017998, IPR002194, IPR002423, IPR027409, IPR027413, IPR027410, P17987",1,7X3J,Mutant,P17987,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,9
7X3U,,,,,,7X3U,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,cryo-EM structure of human TRiC-ADP,STRUCTURAL PROTEIN,"TCP1, CCT1, CCTA",,"GO:0001669, GO:0044297, GO:0005813, GO:0005832, GO:0005829, GO:0070062, GO:0005794, GO:0000792, GO:0005874, GO:0000242, GO:0002199, GO:0005524, GO:0016887, GO:0140662, GO:0044183, GO:0003723, GO:0031625, GO:0051082, GO:0007339, GO:0061077, GO:1904851, GO:1904871, GO:0051973, GO:1904874, GO:0032212, GO:0006457, GO:0050821, GO:2000109, GO:0090666, GO:1901998, GO:0044053, GO:0007021, IPR012715, IPR017998, IPR002194, IPR002423, IPR027409, IPR027413, IPR027410, P17987",1,7X3U,Mutant,P17987,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,9
7XZH,,,,,,7XZH,cryo-EM structure of human LRRC8A,Cryo-EM structure of human LRRC8A,MEMBRANE PROTEIN,"LRRC8A, KIAA1437, LRRC8, SWELL1, UNQ221/PRO247",,"GO:0009986, GO:0034702, GO:0016020, GO:0005886, GO:0140360, GO:0042802, GO:0005225, GO:0098656, GO:0006820, GO:0015810, GO:0006884, GO:0001678, GO:1902476, GO:0140361, GO:0032024, GO:0045663, GO:0002329, GO:0034214, GO:0006970, GO:0007283, GO:0015734, IPR001611, IPR003591, IPR032675, IPR021040, Q8IWT6, Generic PDBTM",1,7XZH,wildtype,Q8IWT6,UniProt,C42 H82 N O10 P,792.075,P5S,"O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC(C(=O)O)N)OC(=O)CCCCCCCCCCCCCCCCC,2
7XZH,,,,,,7XZH,cryo-EM structure of human LRRC8A,Cryo-EM structure of human LRRC8A,MEMBRANE PROTEIN,"LRRC8A, KIAA1437, LRRC8, SWELL1, UNQ221/PRO247",,"GO:0009986, GO:0034702, GO:0016020, GO:0005886, GO:0140360, GO:0042802, GO:0005225, GO:0098656, GO:0006820, GO:0015810, GO:0006884, GO:0001678, GO:1902476, GO:0140361, GO:0032024, GO:0045663, GO:0002329, GO:0034214, GO:0006970, GO:0007283, GO:0015734, IPR001611, IPR003591, IPR032675, IPR021040, Q8IWT6, Generic PDBTM",1,7XZH,wildtype,Q8IWT6,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,4
7Y63,,,,,,7Y63,Structure of human SID1 family,ApoSIDT2-pH7.4,MEMBRANE PROTEIN,"SIDT2, CGI-40, PSEC0072, UNQ685/PRO1325",,"GO:0005765, GO:0005764, GO:0005886, GO:0035650, GO:0035612, GO:0003677, GO:0003725, GO:0051032, GO:0051033, GO:0000902, GO:0042593, GO:0061178, GO:0009749, GO:0006401, GO:0050658, GO:0003323, GO:0044342, IPR025958, Q8NBJ9",1,7Y63,wildtype,Q8NBJ9,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7Y68,,,,,,7Y68,Structure of human SID1 family,SIDT2-pH5.5 plus miRNA,MEMBRANE PROTEIN,"SIDT2, CGI-40, PSEC0072, UNQ685/PRO1325",,"GO:0005765, GO:0005764, GO:0005886, GO:0035650, GO:0035612, GO:0003677, GO:0003725, GO:0051032, GO:0051033, GO:0000902, GO:0042593, GO:0061178, GO:0009749, GO:0006401, GO:0050658, GO:0003323, GO:0044342, IPR025958, Q8NBJ9",1,7Y68,wildtype,Q8NBJ9,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7Y69,,,,,,7Y69,Structure of SID1 family,ApoSIDT2-pH5.5,MEMBRANE PROTEIN,"SIDT2, CGI-40, PSEC0072, UNQ685/PRO1325",,"GO:0005765, GO:0005764, GO:0005886, GO:0035650, GO:0035612, GO:0003677, GO:0003725, GO:0051032, GO:0051033, GO:0000902, GO:0042593, GO:0061178, GO:0009749, GO:0006401, GO:0050658, GO:0003323, GO:0044342, IPR025958, Q8NBJ9",1,7Y69,wildtype,Q8NBJ9,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVE,,,,,,7YVE,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH027 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7YVE,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVG,,,,,,7YVG,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH132 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7YVG,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVI,,,,,,7YVI,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH236 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7YVI,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVK,,,,,,7YVK,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH272 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7YVK,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVN,,,,,,7YVN,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH281 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7YVN,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YVO,,,,,,7YVO,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH027/132 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,,,,2,7YVO,Mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7YVP,,,,,,7YVP,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH272/281 Fab,ANTIVIRAL PROTEIN/VIRAL PROTEIN,,,,1,7YVP,Mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7ZT2,,,,,,7ZT2,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex with human MR1 bound to 5-OP-RU,IMMUNE SYSTEM,MR1,,"GO:0031901, GO:0005783, GO:0005789, GO:0009897, GO:0005615, GO:0000139, GO:0031902, GO:0042612, GO:0005886, GO:0030881, GO:0032393, GO:0042608, GO:0019884, GO:0002474, GO:0050829, GO:0050830, GO:0006955, GO:0045087, GO:0002854, GO:0033077, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, IPR011161, IPR037055, IPR011162, IPR001039, Q95460",1,7ZT2,wildtype,Q95460,UniProt,C12 H20 N4 O6,316.31,2LJ,"1-deoxy-1-({2,6-dioxo-5-[(E)-propylideneamino]-1,2,3,6-tetrahydropyrimidin-4-yl}amino)-D-ribitol",CCC=NC1=C(NC(=O)NC1=O)NCC(C(C(CO)O)O)O,5
7ZT4,,,,,,7ZT4,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex with human MR1 bound to 6FP,IMMUNE SYSTEM,MR1,,"GO:0031901, GO:0005783, GO:0005789, GO:0009897, GO:0005615, GO:0000139, GO:0031902, GO:0042612, GO:0005886, GO:0030881, GO:0032393, GO:0042608, GO:0019884, GO:0002474, GO:0050829, GO:0050830, GO:0006955, GO:0045087, GO:0002854, GO:0033077, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, IPR011161, IPR037055, IPR011162, IPR001039, Q95460",1,7ZT4,wildtype,Q95460,UniProt,C7 H7 N5 O,177.163,JSO,2-azanyl-6-methyl-3~{H}-pteridin-4-one,Cc1cnc2c(n1)C(=O)NC(=N2)N,5
7ZT5,,,,,,7ZT5,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex in human MR1 bound to 3FSA,IMMUNE SYSTEM,MR1,,"GO:0031901, GO:0005783, GO:0005789, GO:0009897, GO:0005615, GO:0000139, GO:0031902, GO:0042612, GO:0005886, GO:0030881, GO:0032393, GO:0042608, GO:0019884, GO:0002474, GO:0050829, GO:0050830, GO:0006955, GO:0045087, GO:0002854, GO:0033077, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, IPR011161, IPR037055, IPR011162, IPR001039, Q95460",1,7ZT5,wildtype,Q95460,UniProt,C8 H6 O4,166.131,7ZS,3-methanoyl-2-oxidanyl-benzoic acid,c1cc(c(c(c1)C(=O)O)O)C=O,5
7ZT7,,,,,,7ZT7,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex in human MR1 bound to 5FSA,IMMUNE SYSTEM,MR1,,"GO:0031901, GO:0005783, GO:0005789, GO:0009897, GO:0005615, GO:0000139, GO:0031902, GO:0042612, GO:0005886, GO:0030881, GO:0032393, GO:0042608, GO:0019884, GO:0002474, GO:0050829, GO:0050830, GO:0006955, GO:0045087, GO:0002854, GO:0033077, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, IPR011161, IPR037055, IPR011162, IPR001039, Q95460",1,7ZT7,wildtype,Q95460,UniProt,C8 H8 O3,152.147,54G,2-hydroxy-5-methylbenzoic acid,Cc1ccc(c(c1)C(=O)O)O,5
7ZT8,,,,,,7ZT8,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex in human MR1 bound to 3FBA,IMMUNE SYSTEM,MR1,,"GO:0031901, GO:0005783, GO:0005789, GO:0009897, GO:0005615, GO:0000139, GO:0031902, GO:0042612, GO:0005886, GO:0030881, GO:0032393, GO:0042608, GO:0019884, GO:0002474, GO:0050829, GO:0050830, GO:0006955, GO:0045087, GO:0002854, GO:0033077, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, IPR011161, IPR037055, IPR011162, IPR001039, Q95460",1,7ZT8,wildtype,Q95460,UniProt,C8 H8 O2,136.148,OVV,3-methylbenzoic acid,Cc1cccc(c1)C(=O)O,5
7ZT9,,,,,,7ZT9,Promiscuous recognition of MR1 drives self-reactive Mucosal-Associated Invariant T cell responses,Structure of E8 TCR in complex in human MR1 bound to 4FBA,IMMUNE SYSTEM,MR1,,"GO:0031901, GO:0005783, GO:0005789, GO:0009897, GO:0005615, GO:0000139, GO:0031902, GO:0042612, GO:0005886, GO:0030881, GO:0032393, GO:0042608, GO:0019884, GO:0002474, GO:0050829, GO:0050830, GO:0006955, GO:0045087, GO:0002854, GO:0033077, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, IPR011161, IPR037055, IPR011162, IPR001039, Q95460",1,7ZT9,wildtype,Q95460,UniProt,C8 H8 O2,136.148,4MA,4-METHYLBENZOIC ACID,Cc1ccc(cc1)C(=O)O,5
7ZYT,,,,,,7ZYT,Structural and biochemical investigation of selected pathogenic mutants of the human dihydrolipoamide dehydrogenase,Crystal structure of the I318T pathogenic variant of the human dihydrolipoamide dehydrogenase,OXIDOREDUCTASE,"DLD, GCSL, LAD, PHE3",1.8.1.4,"GO:0043159, GO:0005947, GO:0005759, GO:0005967, GO:0005739, GO:0031514, GO:0005634, GO:0045252, GO:0045254, GO:0004148, GO:0050660, GO:0006086, GO:0009083, GO:0045454, GO:0007369, GO:0106077, GO:0006120, GO:0006508, GO:0042391, GO:0048240, IPR036188, IPR023753, IPR016156, IPR006258, IPR001100, IPR004099, IPR012999, P09622",1,7ZYT,Mutant,P09622,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,2
8ACT,,,,,,8ACT,Cryo-EM structure of the folded-back state of human beta-cardiac myosin.,structure of the human beta-cardiac myosin folded-back off state,CONTRACTILE PROTEIN,"MYH7, MYHCB",,"GO:0005859, GO:0030016, GO:0016459, GO:0032982, GO:0016460, GO:0030017, GO:0001725, GO:0030018, GO:0051015, GO:0005524, GO:0005516, GO:0000146, GO:0007512, GO:0046034, GO:0060048, GO:0014898, GO:0006936, GO:0030049, GO:0002027, GO:0031449, GO:0002026, GO:0014728, GO:0045214, GO:0003009, GO:0006941, GO:0014883, GO:0055010, IPR000048, IPR036961, IPR001609, IPR004009, IPR008989, IPR002928, IPR027417, IPR014751, P12883",1,8ACT,wildtype,P12883,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,4
8D4F,,,,,,8D4F,Self-assembly and structure of a clathrin-independent AP-1:Arf1 tubular membrane coat.,"beta-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide incorporated wide(r) membrane tubes",PROTEIN TRANSPORT,"AP1B1, ADTB1, BAM22, CLAPB2",,"GO:0030121, GO:0030659, GO:0005829, GO:0005769, GO:0005794, GO:0000139, GO:0043231, GO:0005765, GO:0032588, GO:0030276, GO:0019901, GO:0110010, GO:0007368, GO:0007507, GO:0006886, GO:0001822, GO:1903232, GO:0060155, GO:0016192, IPR026739, IPR016342, IPR011989, IPR016024, IPR000225, IPR015151, IPR002553, IPR008152, IPR013041, IPR013037, IPR009028, IPR012295, Q10567",1,8D4F,Mutant,Q10567,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,8
8D4G,,,,,,8D4G,Self-assembly and structure of a clathrin-independent AP-1:Arf1 tubular membrane coat.,"gamma-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide incorporated wide(r) membrane tubes",PROTEIN TRANSPORT,"AP1B1, ADTB1, BAM22, CLAPB2",,"GO:0030121, GO:0030659, GO:0005829, GO:0005769, GO:0005794, GO:0000139, GO:0043231, GO:0005765, GO:0032588, GO:0030276, GO:0019901, GO:0110010, GO:0007368, GO:0007507, GO:0006886, GO:0001822, GO:1903232, GO:0060155, GO:0016192, IPR026739, IPR016342, IPR011989, IPR016024, IPR000225, IPR015151, IPR002553, IPR008152, IPR013041, IPR013037, IPR009028, IPR012295, Q10567",1,8D4G,Mutant,Q10567,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,8
8DIS,,,,,,8DIS,CryoEM structure of Influenza A virus  A/Melbourne/1/1946 (H1N1) hemagglutinin bound to CR6261 Fab,CryoEM structure of Influenza A virus A/Melbourne/1/1946 (H1N1) hemagglutinin bound to CR6261 Fab,VIRAL PROTEIN/IMMUNE SYSTEM,HA,,,1,8DIS,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
8E1P,,,,,,8E1P,Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.,Crystal structure of BG505 SOSIP.v4.1-GT1.2 trimer in complex with gl-PGV20 and PGT124 Fabs,VIRAL PROTEIN/IMMUNE SYSTEM,,,,1,8E1P,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,14
8E8R,,,,,,8E8R,High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,9H2 Fab-Sabin poliovirus 3 complex,VIRUS/IMMUNE SYSTEM,,,"GO:0005198, GO:0046718, GO:0019062, IPR001676, IPR033703, IPR029053",1,8E8R,wildtype,B2X7G7,UniProt,C16 H32 O2,256.424,PLM,PALMITIC ACID,CCCCCCCCCCCCCCCC(=O)O,7
8E8S,,,,,,8E8S,High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,9H2 Fab-poliovirus 2 complex,VIRUS/IMMUNE SYSTEM,,,"GO:0005198, GO:0046718, GO:0019062, IPR001676, IPR033703, IPR029053",1,8E8S,wildtype,Q8QNU4,UniProt,C16 H32 O2,256.424,PLM,PALMITIC ACID,CCCCCCCCCCCCCCCC(=O)O,7
8E8X,,,,,,8E8X,High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,9H2 Fab-Sabin poliovirus 3 complex,VIRUS/IMMUNE SYSTEM,,,"GO:0005198, GO:0046718, GO:0019062, IPR001676, IPR033703, IPR029053",1,8E8X,wildtype,B2X7G8,UniProt,C16 H32 O2,256.424,PLM,PALMITIC ACID,CCCCCCCCCCCCCCCC(=O)O,7
8E8Y,,,,,,8E8Y,High resolution cryo EM structures show a human monoclonal antibody binds into the canyon to neutralize all three serotypes of poliovirus,9H2 Fab-Sabin poliovirus 2 complex,VIRUS/IMMUNE SYSTEM,,"3.4.22.29, 3.6.1.15, 3.4.22.28, 2.7.7.48","GO:0030659, GO:0044162, GO:0042025, GO:0039618, GO:0005524, GO:0004197, GO:0046872, GO:0005216, GO:0017111, GO:0003723, GO:0003724, GO:0003968, GO:0005198, GO:0006351, GO:0075509, GO:0039520, GO:0039707, GO:0044694, GO:0051259, GO:0006508, GO:0018144, GO:0039657, GO:0039503, GO:0039522, GO:0039694, GO:0019062, IPR043502, IPR000605, IPR014759, IPR027417, IPR014838, IPR036203, IPR044067, IPR000081, IPR000199, IPR009003, IPR043504, IPR003138, IPR002527, IPR001676, IPR043128, IPR033703, IPR001205, IPR007094, IPR029053",1,8E8Y,wildtype,Q8B3S1,UniProt,C16 H32 O2,256.424,PLM,PALMITIC ACID,CCCCCCCCCCCCCCCC(=O)O,7
8EBZ,,,,,,8EBZ,Reduced dynamic complexity allows structure elucidation of an excited state of KRAS G13D .,Crystal Structure of GMPPNP-bound KRAS-G13D mutant at 1.2 Ang resolution,ONCOPROTEIN,"KRAS, KRAS2, RASK2",3.6.5.2,"GO:0005737, GO:0005829, GO:0005789, GO:0031234, GO:0005925, GO:0000139, GO:0016020, GO:0005741, GO:0005886, GO:0003925, GO:0019003, GO:0005525, GO:0003924, GO:0042802, GO:0044877, GO:0030036, GO:0038002, GO:0060441, GO:0021897, GO:0014009, GO:0048873, GO:0000165, GO:0030857, GO:0043524, GO:0051402, GO:0008284, GO:0010628, GO:0060252, GO:0001934, GO:0035022, GO:0016601, GO:0007265, GO:0048169, GO:0031647, GO:0032228, GO:0035914, GO:0051146, GO:0060509, GO:0008542, IPR027417, IPR005225, IPR001806, IPR020849",1,8EBZ,Mutant,P01116-2,UniProt,C10 H17 N6 O13 P3,522.196,GNP,PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N=C(NC2=O)N,2
8EEW,,,,,,8EEW,Opa1 helical structures give perspective to mitochondrial dysfunction,CryoEM of the soluble OPA1 dimer from the GDP-AlFx bound helical assembly on a lipid membrane,LIPID BINDING PROTEIN,"OPA1, KIAA0567",3.6.5.5,"GO:1904115, GO:0005737, GO:0005829, GO:0030425, GO:0016020, GO:0005874, GO:0030061, GO:0005743, GO:0005758, GO:0031966, GO:0005741, GO:0005739, GO:0005654, GO:1901612, GO:0005525, GO:0003924, GO:0000287, GO:0008017, GO:0070300, GO:0006915, GO:0019896, GO:0090398, GO:0046039, GO:0007007, GO:0097749, GO:0000266, GO:0008053, GO:0000002, GO:0007005, GO:0043066, GO:1902236, GO:0090201, GO:0001843, GO:0051259, GO:0007601, IPR022812, IPR001401, IPR045063, IPR030381, IPR033047, IPR045817, IPR027417, O60313",1,8EEW,wildtype,O60313,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,2
8EFF,,,,,,8EFF,Opa1 helical structures give perspective to mitochondrial dysfunction,CryoEM of the soluble OPA1 tetramer from the GDP-AlFx bound helical assembly on a lipid membrane,LIPID BINDING PROTEIN,"OPA1, KIAA0567",3.6.5.5,"GO:1904115, GO:0005737, GO:0005829, GO:0030425, GO:0016020, GO:0005874, GO:0030061, GO:0005743, GO:0005758, GO:0031966, GO:0005741, GO:0005739, GO:0005654, GO:1901612, GO:0005525, GO:0003924, GO:0000287, GO:0008017, GO:0070300, GO:0006915, GO:0019896, GO:0090398, GO:0046039, GO:0007007, GO:0097749, GO:0000266, GO:0008053, GO:0000002, GO:0007005, GO:0043066, GO:1902236, GO:0090201, GO:0001843, GO:0051259, GO:0007601, IPR022812, IPR001401, IPR045063, IPR030381, IPR033047, IPR045817, IPR027417, O60313",1,8EFF,wildtype,O60313,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,2
8EFR,,,,,,8EFR,Opa1 helical structures give perspective to mitochondrial dysfunction,CryoEM of the soluble OPA1 interfaces with GDP-AlFx bound from the helical assembly on a lipid membrane,LIPID BINDING PROTEIN,"OPA1, KIAA0567",3.6.5.5,"GO:1904115, GO:0005737, GO:0005829, GO:0030425, GO:0016020, GO:0005874, GO:0030061, GO:0005743, GO:0005758, GO:0031966, GO:0005741, GO:0005739, GO:0005654, GO:1901612, GO:0005525, GO:0003924, GO:0000287, GO:0008017, GO:0070300, GO:0006915, GO:0019896, GO:0090398, GO:0046039, GO:0007007, GO:0097749, GO:0000266, GO:0008053, GO:0000002, GO:0007005, GO:0043066, GO:1902236, GO:0090201, GO:0001843, GO:0051259, GO:0007601, IPR022812, IPR001401, IPR045063, IPR030381, IPR033047, IPR045817, IPR027417, O60313",1,8EFR,wildtype,O60313,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,2
8ESM,,,,,,8ESM,Mechanism of action for small-molecule inhibitors of triacylglycerol synthesis.,Human triacylglycerol synthesizing enzyme DGAT1 in complex with T863 inhibitor,TRANSFERASE/TRANSFERASE INHIBITOR,"DGAT1, AGRP1, DGAT","2.3.1.20, 2.3.1.76","GO:0005789, GO:0005886, GO:0035579, GO:0003846, GO:0016746, GO:0004144, GO:0042802, GO:0008374, GO:0050252, GO:0046339, GO:0055089, GO:0019915, GO:0035336, GO:0006640, GO:0019432, GO:0006641, GO:0034379, IPR027251, IPR004299, IPR014371, O75907, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.<em>O</em>-acyltransferases.diacylglycerol O-acyltransferase 1 (DGAT1) with bound T863 inhibitor",1,8ESM,wildtype,O75907,UniProt,C22 H26 N4 O3,394.467,WS0,"{(1r,4r)-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl}acetic acid",CC1(C(=Nc2c(ncnc2O1)N)c3ccc(cc3)C4CCC(CC4)CC(=O)O)C,2
8ETM,,,,,,8ETM,Mechanism of action for small-molecule inhibitors of triacylglycerol synthesis.,Human triacylglycerol synthesizing enzyme DGAT1 in complex with DGAT1IN1 inhibitor,TRANSFERASE/TRANSFERASE INHIBITOR,"DGAT1, AGRP1, DGAT","2.3.1.20, 2.3.1.76","GO:0005789, GO:0005886, GO:0035579, GO:0003846, GO:0016746, GO:0004144, GO:0042802, GO:0008374, GO:0050252, GO:0046339, GO:0055089, GO:0019915, GO:0035336, GO:0006640, GO:0019432, GO:0006641, GO:0034379, IPR027251, IPR004299, IPR014371, O75907, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.<em>O</em>-acyltransferases.diacylglycerol O-acyltransferase 1 (DGAT1) with bound T863 inhibitor, Generic PDBTM",1,8ETM,wildtype,O75907,UniProt,C30 H28 F3 N3 O4,551.556,WTT,"[(1S,4r)-4-{4-[(4S)-2-({[4-(trifluoromethoxy)phenyl]methyl}carbamoyl)imidazo[1,2-a]pyridin-6-yl]phenyl}cyclohexyl]acetic acid",c1cc(ccc1CNC(=O)c2cn3cc(ccc3n2)c4ccc(cc4)C5CCC(CC5)CC(=O)O)OC(F)(F)F,2
8EZA,,,,,,8EZA,Cryo-EM visualization of DNA-PKcs structural intermediates in NHEJ.,NHEJ Long-range complex with PAXX,DNA BINDING PROTEIN/DNA,"PAXX, C9orf142, XLS",,"GO:0005737, GO:0070419, GO:0005654, GO:0005634, GO:0035861, GO:0070182, GO:0042802, GO:0060090, GO:0042803, GO:0006974, GO:0006303, IPR027873, Q9BUH6",1,8EZA,wildtype,Q9BUH6,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,11
8EZB,,,,,,8EZB,Cryo-EM visualization of DNA-PKcs structural intermediates in NHEJ.,NHEJ Long-range complex with ATP,DNA BINDING PROTEIN/DNA,"XRCC5, G22P2",3.6.4,"GO:0000781, GO:0005829, GO:0070418, GO:0005576, GO:0043564, GO:0016020, GO:0070419, GO:0000783, GO:0005730, GO:0005654, GO:0005634, GO:0005886, GO:0032991, GO:0032993, GO:1990904, GO:0034774, GO:0090734, GO:0032040, GO:0005524, GO:0008094, GO:0003684, GO:0003677, GO:0045027, GO:0003678, GO:0003690, GO:0008047, GO:0016787, GO:0044877, GO:0003723, GO:0042162, GO:0000976, GO:0034511, GO:0031625, GO:0002218, GO:0007420, GO:0071475, GO:0006974, GO:0071398, GO:0071480, GO:1990830, GO:0071481, GO:0006310, GO:0006302, GO:0006303, GO:0060218, GO:0071425, GO:0045087, GO:1904430, GO:0045892, GO:0022008, GO:0043085, GO:0050769, GO:0045860, GO:0051973, GO:0032212, GO:0070198, GO:0000725, GO:0048660, GO:0032204, GO:0009410, GO:0034462, GO:0000723, IPR006164, IPR024193, IPR005160, IPR036494, IPR005161, IPR014893, IPR016194, IPR002035, IPR036465, P13010",2,8EZB,wildtype,P13010,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,11
8FAZ,,,,,,8FAZ,Structural insights into BCDX2 complex function in homologous recombination,Cryo-EM structure of the human BCDX2 complex,RECOMBINATION,"RAD51B, RAD51L1, REC2",,"GO:0005654, GO:0005634, GO:0033063, GO:0005657, GO:0005524, GO:0008094, GO:0140664, GO:0003677, GO:0003690, GO:0003697, GO:0001832, GO:0006310, GO:0006281, GO:0000724, GO:0008284, GO:0010971, GO:0007131, GO:0061053, IPR003593, IPR013632, IPR016467, IPR027417, IPR030548, IPR020588, O15315",1,8FAZ,wildtype,O15315,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8FAZ,,,,,,8FAZ,Structural insights into BCDX2 complex function in homologous recombination,Cryo-EM structure of the human BCDX2 complex,RECOMBINATION,"RAD51C, RAD51L2",,"GO:0030054, GO:0005737, GO:0005829, GO:0043231, GO:0005739, GO:0005654, GO:0005634, GO:0048471, GO:0033063, GO:0033065, GO:0005657, GO:0005524, GO:0140664, GO:0008821, GO:0003677, GO:0006310, GO:0006281, GO:0000724, GO:0007066, GO:0007141, GO:0000707, GO:0010971, GO:0007131, GO:0007062, GO:0007283, GO:0000722, IPR013632, IPR016467, IPR027417, IPR020588, O43502",2,8FAZ,,O43502,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,6
8FCN,,,,,,8FCN,The p97/VCP adapter UBXD1 drives AAA+ remodeling and ring opening through multi-domain tethered interactions.,Cryo-EM structure of p97:UBXD1 VIM-only state,"CHAPERONE, HYDROLASE","UBXN6, UBXD1, UBXDC2",,"GO:0005737, GO:0005829, GO:0031901, GO:0005768, GO:0070062, GO:0019898, GO:0031902, GO:0005765, GO:0005815, GO:0005634, GO:0032991, GO:0032510, GO:0036503, GO:0016236, IPR036339, IPR018997, IPR029071, IPR001012, IPR042774, Q9BZV1",1,8FCN,wildtype,Q9BZV1,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8FCY,,,,,,8FCY,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in microtubule-bound state,MOTOR PROTEIN,"DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325",,"GO:1904115, GO:0035578, GO:0005938, GO:0005813, GO:0005868, GO:0005881, GO:0005829, GO:0030286, GO:0070062, GO:0005576, GO:0030175, GO:0016020, GO:0005874, GO:0005524, GO:0045505, GO:0051959, GO:0008569, GO:0003723, GO:0051301, GO:0031122, GO:0051293, GO:0007018, GO:0072382, GO:0000278, GO:0007052, GO:0007097, GO:0033962, GO:0120162, GO:0032388, GO:1905832, GO:0090235, GO:0060236, GO:0008090, GO:0034063, IPR003593, IPR035699, IPR035706, IPR041658, IPR042219, IPR042222, IPR043157, IPR041466, IPR041228, IPR043160, IPR024743, IPR024317, IPR004273, IPR013602, IPR013594, IPR042228, IPR027417, Q14204",1,8FCY,wildtype,Q14204,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,2
8FCY,,,,,,8FCY,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in microtubule-bound state,MOTOR PROTEIN,"DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325",,,1,8FCY,wildtype,Q14204,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8FD6,,,,,,8FD6,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state in the buffer containing ATP-Vi,MOTOR PROTEIN,"DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325",,"GO:1904115, GO:0035578, GO:0005938, GO:0005813, GO:0005868, GO:0005881, GO:0005829, GO:0030286, GO:0070062, GO:0005576, GO:0030175, GO:0016020, GO:0005874, GO:0005524, GO:0045505, GO:0051959, GO:0008569, GO:0003723, GO:0051301, GO:0031122, GO:0051293, GO:0007018, GO:0072382, GO:0000278, GO:0007052, GO:0007097, GO:0033962, GO:0120162, GO:0032388, GO:1905832, GO:0090235, GO:0060236, GO:0008090, GO:0034063, IPR003593, IPR035699, IPR035706, IPR041658, IPR042219, IPR042222, IPR043157, IPR041466, IPR041228, IPR043160, IPR024743, IPR024317, IPR004273, IPR013602, IPR013594, IPR042228, IPR027417, Q14204",1,8FD6,wildtype,Q14204,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,2
8FD6,,,,,,8FD6,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state in the buffer containing ATP-Vi,MOTOR PROTEIN,"DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325",,"GO:1904115, GO:0035578, GO:0005938, GO:0005813, GO:0005868, GO:0005881, GO:0005829, GO:0030286, GO:0070062, GO:0005576, GO:0030175, GO:0016020, GO:0005874, GO:0005524, GO:0045505, GO:0051959, GO:0008569, GO:0003723, GO:0051301, GO:0031122, GO:0051293, GO:0007018, GO:0072382, GO:0000278, GO:0007052, GO:0007097, GO:0033962, GO:0120162, GO:0032388, GO:1905832, GO:0090235, GO:0060236, GO:0008090, GO:0034063, IPR003593, IPR035699, IPR035706, IPR041658, IPR042219, IPR042222, IPR043157, IPR041466, IPR041228, IPR043160, IPR024743, IPR024317, IPR004273, IPR013602, IPR013594, IPR042228, IPR027417, Q14204",1,8FD6,wildtype,Q14204,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8FD6,,,,,,8FD6,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state in the buffer containing ATP-Vi,MOTOR PROTEIN,"DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325",,"GO:1904115, GO:0035578, GO:0005938, GO:0005813, GO:0005868, GO:0005881, GO:0005829, GO:0030286, GO:0070062, GO:0005576, GO:0030175, GO:0016020, GO:0005874, GO:0005524, GO:0045505, GO:0051959, GO:0008569, GO:0003723, GO:0051301, GO:0031122, GO:0051293, GO:0007018, GO:0072382, GO:0000278, GO:0007052, GO:0007097, GO:0033962, GO:0120162, GO:0032388, GO:1905832, GO:0090235, GO:0060236, GO:0008090, GO:0034063, IPR003593, IPR035699, IPR035706, IPR041658, IPR042219, IPR042222, IPR043157, IPR041466, IPR041228, IPR043160, IPR024743, IPR024317, IPR004273, IPR013602, IPR013594, IPR042228, IPR027417, Q14204",1,8FD6,wildtype,Q14204,UniProt,O4 V,114.939,VO4,VANADATE ION,[O-][V](=O)([O-])[O-],4
8FDT,,,,,,8FDT,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state with LIS1 complex in the buffer containing ATP-Vi,MOTOR PROTEIN,"DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325",,"GO:1904115, GO:0035578, GO:0005938, GO:0005813, GO:0005868, GO:0005881, GO:0005829, GO:0030286, GO:0070062, GO:0005576, GO:0030175, GO:0016020, GO:0005874, GO:0005524, GO:0045505, GO:0051959, GO:0008569, GO:0003723, GO:0051301, GO:0031122, GO:0051293, GO:0007018, GO:0072382, GO:0000278, GO:0007052, GO:0007097, GO:0033962, GO:0120162, GO:0032388, GO:1905832, GO:0090235, GO:0060236, GO:0008090, GO:0034063, IPR003593, IPR035699, IPR035706, IPR041658, IPR042219, IPR042222, IPR043157, IPR041466, IPR041228, IPR043160, IPR024743, IPR024317, IPR004273, IPR013602, IPR013594, IPR042228, IPR027417, Q14204",1,8FDT,wildtype,Q14204,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8FDT,,,,,,8FDT,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state with LIS1 complex in the buffer containing ATP-Vi,MOTOR PROTEIN,"DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325",,,1,8FDT,wildtype,Q14204,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,4
8FDU,,,,,,8FDU,Microtubule-binding-induced allostery triggers LIS1 dissociation from dynein prior to cargo transport.,Engineered human dynein motor domain in the microtubule-unbound state with LIS1 complex in the buffer containing ATP-Vi (local refined on AAA3-AAA5 and LIS1),MOTOR PROTEIN,"DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325",,"GO:1904115, GO:0035578, GO:0005938, GO:0005813, GO:0005868, GO:0005881, GO:0005829, GO:0030286, GO:0070062, GO:0005576, GO:0030175, GO:0016020, GO:0005874, GO:0005524, GO:0045505, GO:0051959, GO:0008569, GO:0003723, GO:0051301, GO:0031122, GO:0051293, GO:0007018, GO:0072382, GO:0000278, GO:0007052, GO:0007097, GO:0033962, GO:0120162, GO:0032388, GO:1905832, GO:0090235, GO:0060236, GO:0008090, GO:0034063, IPR003593, IPR035699, IPR035706, IPR041658, IPR042219, IPR042222, IPR043157, IPR041466, IPR041228, IPR043160, IPR024743, IPR024317, IPR004273, IPR013602, IPR013594, IPR042228, IPR027417, Q14204",1,8FDU,wildtype,Q14204,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8FUG,,,,,,8FUG,Stacked binding of a PET ligand to Alzheimer's tau paired helical filaments.,Alzheimer's disease paired-helical filament in complex with PET tracer GTP-1,PROTEIN FIBRIL,"MAPT, MAPTL, MTBT1, TAU",,"GO:0030673, GO:0030424, GO:1904115, GO:0044297, GO:0005737, GO:0036464, GO:0005829, GO:0030425, GO:0043197, GO:0005576, GO:0097386, GO:0030426, GO:0044304, GO:0045121, GO:0005874, GO:0015630, GO:0005739, GO:0097418, GO:0043005, GO:0043025, GO:0034399, GO:0016607, GO:0005634, GO:0005886, GO:0036477, GO:0045298, GO:0003779, GO:0034185, GO:0051087, GO:0003677, GO:0003690, GO:0034452, GO:0019899, GO:0099077, GO:0051879, GO:0042802, GO:0071813, GO:0008017, GO:0099609, GO:0003680, GO:0035091, GO:1902936, GO:0019901, GO:0051721, GO:0030674, GO:0003723, GO:0043565, GO:0017124, GO:0003697, GO:0006919, GO:1990000, GO:0048143, GO:0061564, GO:0098930, GO:0019896, GO:0007267, GO:1990416, GO:0034605, GO:1990090, GO:0034614, GO:0021954, GO:0031122, GO:0048699, GO:0006475, GO:0048312, GO:0007611, GO:0007613, GO:0001774, GO:0000226, GO:0046785, GO:1903748, GO:0010629, GO:0033673, GO:0090258, GO:0010917, GO:1904428, GO:1902988, GO:0031175, GO:0072386, GO:0045773, GO:1905689, GO:0031116, GO:1901216, GO:1903829, GO:1902474, GO:0032930, GO:0051260, GO:0051258, GO:0010506, GO:0050848, GO:1900034, GO:0033044, GO:1900452, GO:0070507, GO:0031113, GO:0031110, GO:0090140, GO:0048167, GO:0010288, GO:0016072, GO:0034063, GO:0097435, GO:0007416, GO:0050808, IPR001084, IPR002955, P10636",1,8FUG,wildtype,P10636,UniProt,C17 H19 F N4,298.358,Y9H,"(5S)-2-[4-(2-fluoroethyl)piperidin-1-yl]pyrimido[1,2-a]benzimidazole",c1ccc2c(c1)nc3n2ccc(n3)N4CCC(CC4)CCF,2
8FZB,,,,,,8FZB,The FAM86 domain of FAM86A confers substrate specificity to promote EEF2-Lys525 methylation.,Crystal structure of human FAM86A,TRANSFERASE,"EEF2KMT, FAM86A, SB153",2.1.1,"GO:0005737, GO:0005829, GO:0032991, GO:0042054, GO:0016279, GO:0018023, GO:0006479, IPR029426, IPR019410, IPR029063, Q96G04",1,8FZB,wildtype,Q96G04,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,2
8G3C,,,,,,8G3C,Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.,"Crystal structure of human WDR5 in complex with N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-6-methyl-4-oxo-4H-pyran-2-carboxamide (compound 1, WDR5-MYC PPI inhibitor)",ONCOPROTEIN/INHIBITOR,"WDR5, BIG3",,"GO:0140672, GO:0000123, GO:0035097, GO:0072686, GO:0071339, GO:0044665, GO:0044666, GO:0044545, GO:0005654, GO:0005634, GO:0048188, GO:0042393, GO:0035064, GO:0006325, GO:0006094, GO:0043966, GO:0044154, GO:0051568, GO:0043984, GO:0043981, GO:0043982, GO:0051572, GO:0031175, GO:0045722, GO:0051571, GO:0045893, GO:0051726, GO:0051302, GO:1900095, GO:0045995, GO:0031063, GO:0006357, GO:0006355, GO:0090043, GO:0001501, IPR020472, IPR015943, IPR001680, IPR019775, IPR036322, P61964",1,8G3C,wildtype,P61964,UniProt,C21 H16 N2 O4,360.363,YJN,"N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-6-methyl-4-oxo-4H-pyran-2-carboxamide",CC1=CC(=O)C(=C(O1)C(=O)NCc2ccc(cc2)c3ccccc3C#N)O,2
8G3E,,,,,,8G3E,Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.,"Crystal structure of human WDR5 in complex with (1M)-N-[(3,5-difluoro[1,1'-biphenyl]-4-yl)methyl]-6-methyl-4-oxo-1-(pyridin-3-yl)-1,4-dihydropyridazine-3-carboxamide (compound 2, WDR5-MYC inhibitor)",ONCOPROTEIN/INHIBITOR,"WDR5, BIG3",,"GO:0140672, GO:0000123, GO:0035097, GO:0072686, GO:0071339, GO:0044665, GO:0044666, GO:0044545, GO:0005654, GO:0005634, GO:0048188, GO:0042393, GO:0035064, GO:0006325, GO:0006094, GO:0043966, GO:0044154, GO:0051568, GO:0043984, GO:0043981, GO:0043982, GO:0051572, GO:0031175, GO:0045722, GO:0051571, GO:0045893, GO:0051726, GO:0051302, GO:1900095, GO:0045995, GO:0031063, GO:0006357, GO:0006355, GO:0090043, GO:0001501, IPR020472, IPR015943, IPR001680, IPR019775, IPR036322, P61964",1,8G3E,wildtype,P61964,UniProt,C24 H18 F2 N4 O2,432.422,YJR,"(1M)-N-[(3,5-difluoro[1,1'-biphenyl]-4-yl)methyl]-6-methyl-4-oxo-1-(pyridin-3-yl)-1,4-dihydropyridazine-3-carboxamide",CC1=CC(=O)C(=NN1c2cccnc2)C(=O)NCc3c(cc(cc3F)c4ccccc4)F,2
8G8W,,,,,,8G8W,Structural basis of purine nucleotide inhibition of human uncoupling protein 1.,Molecular mechanism of nucleotide inhibition of human uncoupling protein 1,MEMBRANE PROTEIN,"UCP1, SLC25A7, UCP",,"GO:0005743, GO:0005739, GO:1901612, GO:0019003, GO:0005525, GO:0036041, GO:0017077, GO:0032555, GO:0022857, GO:1990845, GO:0050873, GO:0070417, GO:1903495, GO:0071398, GO:0032870, GO:0034614, GO:0002024, GO:1990542, GO:0120162, GO:1902600, GO:1903426, GO:0006357, GO:0009409, GO:0031667, GO:0009266, IPR002030, IPR018108, IPR023395, P25874, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Antiporters.UCP1 mitochondrial uncoupling protein 1, Generic PDBTM",1,8G8W,wildtype,P25874,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,5
8GBJ,,,,,,8GBJ,Structural insights into BCDX2 complex function in homologous recombination,Cryo-EM structure of a human BCDX2/ssDNA complex,RECOMBINATION,"RAD51B, RAD51L1, REC2",,"GO:0005654, GO:0005634, GO:0033063, GO:0005657, GO:0005524, GO:0008094, GO:0140664, GO:0003677, GO:0003690, GO:0003697, GO:0001832, GO:0006310, GO:0006281, GO:0000724, GO:0008284, GO:0010971, GO:0007131, GO:0061053, IPR003593, IPR013632, IPR016467, IPR027417, IPR030548, IPR020588, O15315",1,8GBJ,wildtype,O15315,UniProt,C10 H17 N6 O12 P3,506.196,ANP,PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N,6
8GOU,,,,,,8GOU,Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection.,Omicron BA.4/5 SARS-CoV-2 S in complex with TH003 Fab,VIRAL PROTEIN/ANTIVIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8GOU,Mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8GRS,,,,,,8GRS,human TMEM63A,human TMEM63A,MEMBRANE PROTEIN,"TMEM63A, KIAA0489, KIAA0792",,"GO:0034451, GO:0070062, GO:0043231, GO:0005765, GO:0005886, GO:0035579, GO:0070821, GO:0005227, GO:0008381, GO:0003676, GO:1990760, IPR045122, IPR003864, IPR027815, IPR032880, IPR012677, IPR035979, O94886, Generic PDBTM",1,8GRS,wildtype,O94886,UniProt,C42 H82 N O8 P,760.076,POV,(2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC,2
8GSQ,,,,,,8GSQ,"Structure-based discovery of an antipsychotic drug, paliperidone, as a modulator of human superoxide dismutase 1: a potential therapeutic target in amyotrophic lateral sclerosis.",Structure based studies reveal an atypical antipsychotic drug candidate - Paliperidone as a potent hSOD1 modulator with implications in ALS treatment.,OXIDOREDUCTASE,HEL-S-44,1.15.1.1,"GO:1904115, GO:0005829, GO:0031045, GO:0005615, GO:0005764, GO:0005758, GO:0043025, GO:0005654, GO:0005777, GO:0032991, GO:0005507, GO:0030346, GO:0004784, GO:0008089, GO:0006915, GO:0060088, GO:0071318, GO:0071276, GO:0035865, GO:0035234, GO:0007566, GO:0006749, GO:0060047, GO:0050665, GO:0006879, GO:0007626, GO:0046716, GO:0002262, GO:0051093, GO:0050728, GO:0043524, GO:2000242, GO:0060052, GO:0001541, GO:0032287, GO:0043085, GO:0043410, GO:0050766, GO:0008217, GO:0040014, GO:0060087, GO:0001975, GO:0046677, GO:0097332, GO:0048678, GO:0034465, GO:0046688, GO:0045471, GO:0009408, GO:0042542, GO:0031667, GO:0009410, GO:0001895, GO:0008090, GO:0007605, GO:0007283, GO:0042554, GO:0019226, IPR036423, IPR024134, IPR018152, IPR001424",3,8GSQ,wildtype,V9HWC9,UniProt,C23 H27 F N4 O3,426.484,K4I,"(9~{R})-3-[2-[4-(6-fluoranyl-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-9-oxidanyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one",CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)c4c5ccc(cc5on4)F,7
8HBV,,,,,,8HBV,Structural basis of inhibition of human UCP1 by purine nucleotides,Structure of human UCP1 in the nucleotide-free state,MEMBRANE PROTEIN,"UCP1, SLC25A7, UCP",,"GO:0005743, GO:0005739, GO:1901612, GO:0019003, GO:0005525, GO:0036041, GO:0017077, GO:0032555, GO:0022857, GO:1990845, GO:0050873, GO:0070417, GO:1903495, GO:0071398, GO:0032870, GO:0034614, GO:0002024, GO:1990542, GO:0120162, GO:1902600, GO:1903426, GO:0006357, GO:0009409, GO:0031667, GO:0009266, IPR002030, IPR018108, IPR023395, P25874",1,8HBV,wildtype,P25874,UniProt,C44 H88 N O8 P,790.145,PC1,"1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,4
8HBW,,,,,,8HBW,Structural basis of inhibition of human UCP1 by purine nucleotides,Structure of human UCP1 in the ATP-bound state,MEMBRANE PROTEIN,"UCP1, SLC25A7, UCP",,"GO:0005743, GO:0005739, GO:1901612, GO:0019003, GO:0005525, GO:0036041, GO:0017077, GO:0032555, GO:0022857, GO:1990845, GO:0050873, GO:0070417, GO:1903495, GO:0071398, GO:0032870, GO:0034614, GO:0002024, GO:1990542, GO:0120162, GO:1902600, GO:1903426, GO:0006357, GO:0009409, GO:0031667, GO:0009266, IPR002030, IPR018108, IPR023395, P25874",1,8HBW,wildtype,P25874,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8HBW,,,,,,8HBW,Structural basis of inhibition of human UCP1 by purine nucleotides,Structure of human UCP1 in the ATP-bound state,MEMBRANE PROTEIN,"UCP1, SLC25A7, UCP",,"GO:0005743, GO:0005739, GO:1901612, GO:0019003, GO:0005525, GO:0036041, GO:0017077, GO:0032555, GO:0022857, GO:1990845, GO:0050873, GO:0070417, GO:1903495, GO:0071398, GO:0032870, GO:0034614, GO:0002024, GO:1990542, GO:0120162, GO:1902600, GO:1903426, GO:0006357, GO:0009409, GO:0031667, GO:0009266, IPR002030, IPR018108, IPR023395, P25874",1,8HBW,wildtype,P25874,UniProt,C81 H156 O17 P2,1464.043,CDL,CARDIOLIPIN,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(COP(=O)([O-])OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)O)OC(=O)CCCCCCCCCCCCCCCCC,4
8HBW,,,,,,8HBW,Structural basis of inhibition of human UCP1 by purine nucleotides,Structure of human UCP1 in the ATP-bound state,MEMBRANE PROTEIN,"UCP1, SLC25A7, UCP",,,2,8HBW,wildtype,P25874,,C44 H88 N O8 P,790.145,PC1,"1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,5
8HMP,,,,,,8HMP,Allosteric coupling between G-protein binding and extracellular ligand binding sites in GPR52 revealed by 19 F-NMR and cryo-electron microscopy.,GPR52 with Gs and c17,STRUCTURAL PROTEIN,GNB1,,"GO:0005737, GO:0005829, GO:0070062, GO:1903561, GO:0005834, GO:0005765, GO:0016020, GO:0097381, GO:0005886, GO:0045202, GO:0003924, GO:0051020, GO:0044877, GO:0030159, GO:0007191, GO:0008283, GO:0071870, GO:0071380, GO:0007213, GO:0007186, GO:0007200, GO:0007265, GO:0060041, GO:0050909, GO:0007165, IPR020472, IPR001632, IPR016346, IPR015943, IPR001680, IPR019775, IPR036322, P62873",1,8HMP,Mutant,P62873,UniProt,C24 H22 F3 N3 O3 S,489.51,EN6,N-(2-hydroxyethyl)-5-(hydroxymethyl)-3-methyl-1-[2-[[3-(trifluoromethyl)phenyl]methyl]-1-benzothiophen-7-yl]pyrazole-4-carboxamide,Cc1c(c(n(n1)c2cccc3c2sc(c3)Cc4cccc(c4)C(F)(F)F)CO)C(=O)NCCO,6
8HW2,,,,,,8HW2,Cryo-EM structure of ABC transporter ABCC3,Cryo-EM structure of beta-estradiol 17-(beta-D-glucuronide)-bound human ABC transporter ABCC3 in nanodiscs,MEMBRANE PROTEIN,"ABCC3, CMOAT2, MLP2, MRP3","7.6.2, 7.6.2.2, 7.6.2.3","GO:0009925, GO:0016323, GO:0016020, GO:0005886, GO:0015432, GO:0015431, GO:0140359, GO:0008559, GO:0005524, GO:0016887, GO:0043225, GO:0042626, GO:0015164, GO:0071714, GO:0042910, GO:0015721, GO:0071716, GO:0055085, GO:0150104, GO:0006805, GO:0006855, GO:0042908, IPR003593, IPR011527, IPR036640, IPR003439, IPR017871, IPR005292, IPR027417, O15438, Generic PDBTM",1,8HW2,wildtype,O15438,UniProt,C24 H32 O8,448.506,U38,Estradiol-17beta-glucuronide,CC12CCC3c4ccc(cc4CCC3C1CCC2OC5C(C(C(C(O5)C(=O)O)O)O)O)O,2
8HW4,,,,,,8HW4,Cryo-EM structure of ABC transporter ABCC3,Cryo-EM structure of dehydroepiandrosterone sulfate-bound human ABC transporter ABCC3 in nanodiscs,MEMBRANE PROTEIN,"ABCC3, CMOAT2, MLP2, MRP3","7.6.2, 7.6.2.2, 7.6.2.3","GO:0009925, GO:0016323, GO:0016020, GO:0005886, GO:0015432, GO:0015431, GO:0140359, GO:0008559, GO:0005524, GO:0016887, GO:0043225, GO:0042626, GO:0015164, GO:0071714, GO:0042910, GO:0015721, GO:0071716, GO:0055085, GO:0150104, GO:0006805, GO:0006855, GO:0042908, IPR003593, IPR011527, IPR036640, IPR003439, IPR017871, IPR005292, IPR027417, O15438, Generic PDBTM",1,8HW4,wildtype,O15438,UniProt,C19 H28 O5 S,368.488,ZWY,"17-oxo-8alpha,10alpha,13alpha,14beta-androst-5-en-3alpha-yl hydrogen sulfate",CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C,2
8I1M,,,,,,8I1M,Redox switching mechanism of the adenosine 5'-phosphosulfate kinase domain (APSK2) of human PAPS synthase 2.,Crystal structure of oxidated APSK1 domain from human PAPSS1 in complex with APS and ADP,BIOSYNTHETIC PROTEIN,PAPSS1,,"GO:0004020, GO:0005524, GO:0004781, GO:0034033, GO:0009152, GO:0034030, GO:0000103, IPR002891, IPR025980, IPR027417, IPR015947, IPR014729, IPR024951, IPR002650",1,8I1M,wildtype,Q05BW9,UniProt,C10 H14 N5 O10 P S,427.284,ADX,ADENOSINE-5'-PHOSPHOSULFATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OS(=O)(=O)O)O)O)N,3
8I5B,,,,,,8I5B,Structural mapping of Na v 1.7 antagonists.,Structure of human Nav1.7 in complex with bupivacaine,MEMBRANE PROTEIN,"SCN9A, NENA",,"GO:0030424, GO:0001518, GO:0031402, GO:0005244, GO:0005248, GO:0061368, GO:0006954, GO:0086010, GO:0045759, GO:0019228, GO:0009791, GO:0034765, GO:0009409, GO:0009408, GO:0009636, GO:0019233, GO:0035725, GO:0006814, IPR005821, IPR000048, IPR001696, IPR044564, IPR010526, IPR024583, IPR028803, IPR043203, IPR027359, Q15858, Generic PDBTM",1,8I5B,wildtype,Q15858,UniProt,C18 H28 N2 O,288.428,OJ0,"(2~{S})-1-butyl-~{N}-(2,6-dimethylphenyl)piperidine-2-carboxamide",CCCCN1CCCCC1C(=O)Nc2c(cccc2C)C,10
8I5G,,,,,,8I5G,Structural mapping of Na v 1.7 antagonists.,Structure of human Nav1.7 in complex with PF-05089771,MEMBRANE PROTEIN,SCN1B,,"GO:0005576, GO:0014704, GO:0033268, GO:0043204, GO:0005886, GO:0030315, GO:0001518, GO:0019871, GO:0017080, GO:0044325, GO:0005244, GO:0005248, GO:0086006, GO:0086062, GO:0007411, GO:0061337, GO:0086002, GO:0060048, GO:0007155, GO:0021966, GO:0040011, GO:0051899, GO:0086012, GO:0086047, GO:0019227, GO:0010976, GO:0010765, GO:0060371, GO:0086091, GO:2000649, GO:0060307, GO:0035725, IPR036179, IPR013783, IPR013106, IPR027098, IPR044568, Q07699, Generic PDBTM",1,8I5G,wildtype,Q07699,UniProt,C18 H12 Cl2 F N5 O3 S2,500.354,T70,"4-[2-(5-azanyl-1~{H}-pyrazol-4-yl)-4-chloranyl-phenoxy]-5-chloranyl-2-fluoranyl-~{N}-(1,3-thiazol-4-yl)benzenesulfonamide",c1cc(c(cc1Cl)c2cn[nH]c2N)Oc3cc(c(cc3Cl)S(=O)(=O)Nc4cscn4)F,8
8I5X,,,,,,8I5X,Structural mapping of Na v 1.7 antagonists.,Structure of human Nav1.7 in complex with Vinpocetine,MEMBRANE PROTEIN,"SCN9A, NENA",,"GO:0030424, GO:0001518, GO:0031402, GO:0005244, GO:0005248, GO:0061368, GO:0006954, GO:0086010, GO:0045759, GO:0019228, GO:0009791, GO:0034765, GO:0009409, GO:0009408, GO:0009636, GO:0019233, GO:0035725, GO:0006814, IPR005821, IPR000048, IPR001696, IPR044564, IPR010526, IPR024583, IPR028803, IPR043203, IPR027359, Q15858, Generic PDBTM",1,8I5X,wildtype,Q15858,UniProt,C22 H26 N2 O2,350.454,T7F,Ethyl apovincaminate,CCC12CCCN3C1c4c(c5ccccc5n4C(=C2)C(=O)OCC)CC3,9
8I5Y,,,,,,8I5Y,Structural mapping of Na v 1.7 antagonists.,Structure of human Nav1.7 in complex with vixotrigine,MEMBRANE PROTEIN,"SCN9A, NENA",,"GO:0030424, GO:0001518, GO:0031402, GO:0005244, GO:0005248, GO:0061368, GO:0006954, GO:0086010, GO:0045759, GO:0019228, GO:0009791, GO:0034765, GO:0009409, GO:0009408, GO:0009636, GO:0019233, GO:0035725, GO:0006814, IPR005821, IPR000048, IPR001696, IPR044564, IPR010526, IPR024583, IPR028803, IPR043203, IPR027359, Q15858, Generic PDBTM",1,8I5Y,wildtype,Q15858,UniProt,C44 H85 N O8 P,787.121,PCW,"1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE",CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC,13
8IRU,,,,,,8IRU,Structural genomics of the human dopamine receptor system.,Dopamine Receptor D4R-Gi-Rotigotine complex,MEMBRANE PROTEIN,,,,1,8IRU,wildtype,,,C19 H25 N O S,315.473,R5F,"(6~{S})-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol",CCCN(CCc1cccs1)C2CCc3c(cccc3O)C2,6
8IRV,,,,,,8IRV,Structural genomics of the human dopamine receptor system.,Dopamine Receptor D5R-Gs-Rotigotine complex,MEMBRANE PROTEIN,,,,1,8IRV,wildtype,,,C19 H25 N O S,315.473,R5F,"(6~{S})-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol",CCCN(CCc1cccs1)C2CCc3c(cccc3O)C2,5
8ITY,,,,,,8ITY,Structure of the SNAPc-bound RNA polymerase III preinitiation complex.,human RNA polymerase III pre-initiation complex closed DNA 1,TRANSCRIPTION,"SNAPC4, SNAP190",,"GO:0005654, GO:0005634, GO:0019185, GO:0003677, GO:0016251, GO:0000995, GO:0001006, GO:0042795, GO:0042796, IPR009057, IPR017930, IPR001005, IPR017884, Q5SXM2",3,8ITY,Mutant,Q5SXM2,UniProt,Fe4 S4,351.64,SF4,IRON/SULFUR CLUSTER,[S]12[Fe]3[S]4[Fe]1[S]5[Fe]2[S]3[Fe]45,28
8J19,,,,,,8J19,Structural insights into ligand recognition and activation of the medium-chain fatty acid-sensing receptor GPR84,Cryo-EM structure of the LY237-bound GPR84 receptor-Gi complex,IMMUNE SYSTEM,"GPR84, EX33",,"GO:0005886, GO:0043235, GO:0035579, GO:0070821, GO:0001604, GO:0007218, IPR000276, IPR017452, Q9NQS5",1,8J19,Mutant,Q9NQS5,UniProt,C14 H23 N O2,237.338,SWO,"6-nonylpyridine-2,4-diol",CCCCCCCCCc1cc(cc(n1)O)O,6
8J1N,,,,,,8J1N,Structural basis for the binding of DNP and ATP onto human UCP1,Structure of human UCP1 in the DNP-bound state,MEMBRANE PROTEIN,"UCP1, SLC25A7, UCP",,"GO:0005743, GO:0005739, GO:1901612, GO:0019003, GO:0005525, GO:0036041, GO:0017077, GO:0032555, GO:0022857, GO:1990845, GO:0050873, GO:0070417, GO:1903495, GO:0071398, GO:0032870, GO:0034614, GO:0002024, GO:1990542, GO:0120162, GO:1902600, GO:1903426, GO:0006357, GO:0009409, GO:0031667, GO:0009266, IPR002030, IPR018108, IPR023395, P25874",1,8J1N,wildtype,P25874,UniProt,C6 H4 N2 O5,184.106,DNF,"2,4-DINITROPHENOL",c1cc(c(cc1[N+](=O)[O-])[N+](=O)[O-])O,3
8J1N,,,,,,8J1N,Structural basis for the binding of DNP and ATP onto human UCP1,Structure of human UCP1 in the DNP-bound state,MEMBRANE PROTEIN,"UCP1, SLC25A7, UCP",,"GO:0005743, GO:0005739, GO:1901612, GO:0019003, GO:0005525, GO:0036041, GO:0017077, GO:0032555, GO:0022857, GO:1990845, GO:0050873, GO:0070417, GO:1903495, GO:0071398, GO:0032870, GO:0034614, GO:0002024, GO:1990542, GO:0120162, GO:1902600, GO:1903426, GO:0006357, GO:0009409, GO:0031667, GO:0009266, IPR002030, IPR018108, IPR023395, P25874",2,8J1N,wildtype,P25874,UniProt,C81 H156 O17 P2,1464.043,CDL,CARDIOLIPIN,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(COP(=O)([O-])OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)O)OC(=O)CCCCCCCCCCCCCCCCC,4
8J1N,,,,,,8J1N,Structural basis for the binding of DNP and ATP onto human UCP1,Structure of human UCP1 in the DNP-bound state,MEMBRANE PROTEIN,"UCP1, SLC25A7, UCP",,"GO:0005743, GO:0005739, GO:1901612, GO:0019003, GO:0005525, GO:0036041, GO:0017077, GO:0032555, GO:0022857, GO:1990845, GO:0050873, GO:0070417, GO:1903495, GO:0071398, GO:0032870, GO:0034614, GO:0002024, GO:1990542, GO:0120162, GO:1902600, GO:1903426, GO:0006357, GO:0009409, GO:0031667, GO:0009266, IPR002030, IPR018108, IPR023395, P25874",,8J1N,wildtype,P25874,UniProt,C44 H88 N O8 P,790.145,PC1,"1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,5
8J1Q,,,,,,8J1Q,Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection,CryoEM structure of SARS CoV-2 RBD and Aptamer complex,VIRAL PROTEIN/IMMUNE SYSTEM/DNA,,,,1,8J1Q,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8J26,,,,,,8J26,Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection,CryoEM structure of SARS CoV-2 RBD and Aptamer complex,VIRAL PROTEIN/IMMUNE SYSTEM/DNA,,,,1,8J26,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8JD6,,,,,,8JD6,Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers.,Cryo-EM structure of Gi1-bound metabotropic glutamate receptor mGlu4,MEMBRANE PROTEIN,"GRM4, GPRC1D, MGLUR4",,"GO:0031410, GO:0005886, GO:0098793, GO:0001640, GO:0004930, GO:0008066, GO:0007196, GO:0007268, GO:0007216, GO:0007269, GO:0043410, GO:0043523, GO:0051966, IPR001828, IPR000337, IPR011500, IPR038550, IPR017978, IPR017979, IPR001786, IPR000162, IPR028082, Q14833",1,8JD6,wildtype,Q14833,UniProt,C12 H9 Cl N2 O,232.666,BK0,N-(3-chlorophenyl)pyridine-2-carboxamide,c1ccnc(c1)C(=O)Nc2cccc(c2)Cl,6
8JD6,,,,,,8JD6,Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers.,Cryo-EM structure of Gi1-bound metabotropic glutamate receptor mGlu4,MEMBRANE PROTEIN,"GRM4, GPRC1D, MGLUR4",,"GO:0031410, GO:0005886, GO:0098793, GO:0001640, GO:0004930, GO:0008066, GO:0007196, GO:0007268, GO:0007216, GO:0007269, GO:0043410, GO:0043523, GO:0051966, IPR001828, IPR000337, IPR011500, IPR038550, IPR017978, IPR017979, IPR001786, IPR000162, IPR028082, Q14833",2,8JD6,wildtype,Q14833,,C3 H8 N O6 P,185.072,SEP,PHOSPHOSERINE,C(C(C(=O)O)N)OP(=O)(O)O,7
8OG5,,,,,,8OG5,"Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field",Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 1,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OG5,Mutant,Q9Y4B6,UniProt,C17 H13 F N2,264.297,LQH,"5-(2-fluorophenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline",c1ccc2c(c1)C=C(N3C2=NCC3)c4ccccc4F,4
8OG6,,,,,,8OG6,"Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field",Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 1,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OG6,Mutant,Q9Y4B6,UniProt,C17 H13 F N2,264.297,LQH,"5-(2-fluorophenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline",c1ccc2c(c1)C=C(N3C2=NCC3)c4ccccc4F,2
8OG7,,,,,,8OG7,"Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field",Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 2,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OG7,Mutant,Q9Y4B6,UniProt,C16 H15 Cl N2 O,286.756,VMR,(4~{R})-4-[3-(4-chloranylphenoxy)phenyl]pyrrolidin-2-imine,c1cc(cc(c1)Oc2ccc(cc2)Cl)C3CC(=N)NC3,4
8OG8,,,,,,8OG8,"Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field",Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 3,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OG8,Mutant,Q9Y4B6,UniProt,C21 H20 N2,300.397,VM8,"5-(2-methyl-1-phenyl-propan-2-yl)imidazo[2,1-a]isoquinoline",CC(C)(Cc1ccccc1)c2cc3ccccc3c4n2ccn4,2
8OG9,,,,,,8OG9,"Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field",Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 4,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OG9,Mutant,Q9Y4B6,UniProt,C20 H15 Cl N2,318.8,VM3,"5-[1-(4-chlorophenyl)cyclopropyl]imidazo[2,1-a]isoquinoline",c1ccc2c(c1)cc(n3c2ncc3)C4(CC4)c5ccc(cc5)Cl,2
8OGA,,,,,,8OGA,"Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field",Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 6,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OGA,Mutant,Q9Y4B6,UniProt,C26 H31 N4 O,415.551,VLW,"5-[1-(4-methoxyphenyl)cyclopropyl]-8-(4-methylpiperazin-1-yl)-2,3-dihydro-1~{H}-imidazo[2,1-a]isoquinoline",CN1CCN(CC1)c2ccc3c(c2)C=C([N]4=C3NCC4)C5(CC5)c6ccc(cc6)OC,4
8OGB,,,,,,8OGB,"Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field",Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 8,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OGB,Mutant,Q9Y4B6,UniProt,C25 H32 N6 O,432.561,VN5,"~{N}'-[2-[1-(4-methoxyphenyl)cyclopropyl]-7-(4-methylpiperazin-1-yl)quinazolin-4-yl]ethane-1,2-diamine",CN1CCN(CC1)c2ccc3c(c2)nc(nc3NCCN)C4(CC4)c5ccc(cc5)OC,3
8OGC,,,,,,8OGC,"Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field",Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 11,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OGC,Mutant,Q9Y4B6,UniProt,C27 H33 Cl N6 O,493.044,VMZ,1-[4-[4-(2-azanylethylamino)-2-[1-(4-chlorophenyl)cyclopentyl]quinazolin-7-yl]piperazin-1-yl]ethanone,CC(=O)N1CCN(CC1)c2ccc3c(c2)nc(nc3NCCN)C4(CCCC4)c5ccc(cc5)Cl,6
8OUY,,,,,,8OUY,Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor,"Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex, 3.4 A resolution",DNA BINDING PROTEIN,"RAD51B, RAD51L1, REC2",,"GO:0005654, GO:0005634, GO:0033063, GO:0005657, GO:0005524, GO:0008094, GO:0140664, GO:0003677, GO:0003690, GO:0003697, GO:0001832, GO:0006310, GO:0006281, GO:0000724, GO:0008284, GO:0010971, GO:0007131, GO:0061053, IPR003593, IPR013632, IPR016467, IPR027417, IPR030548, IPR020588, O15315",1,8OUY,wildtype,O15315,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8OUY,,,,,,8OUY,Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor,"Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex, 3.4 A resolution",DNA BINDING PROTEIN,"RAD51D, RAD51L3",,"GO:0005813, GO:0000781, GO:0005737, GO:0005654, GO:0005634, GO:0033063, GO:0005657, GO:0005524, GO:0008094, GO:0140664, GO:0003677, GO:0043015, GO:0003697, GO:0006281, GO:0000724, GO:0036297, GO:0007131, GO:0051726, GO:0042148, GO:0000723, GO:0000722, IPR003593, IPR013632, IPR016467, IPR027417, IPR020588, O75771",3,8OUY,wildtype,O75771,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,7
8OUZ,,,,,,8OUZ,Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor,"Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex, 2.2 A resolution",DNA BINDING PROTEIN,"RAD51B, RAD51L1, REC2",,"GO:0005654, GO:0005634, GO:0033063, GO:0005657, GO:0005524, GO:0008094, GO:0140664, GO:0003677, GO:0003690, GO:0003697, GO:0001832, GO:0006310, GO:0006281, GO:0000724, GO:0008284, GO:0010971, GO:0007131, GO:0061053, IPR003593, IPR013632, IPR016467, IPR027417, IPR030548, IPR020588, O15315",1,8OUZ,wildtype,O15315,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8OUZ,,,,,,8OUZ,Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor,"Human RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2) complex, 2.2 A resolution",DNA BINDING PROTEIN,"RAD51D, RAD51L3",,"GO:0005813, GO:0000781, GO:0005737, GO:0005654, GO:0005634, GO:0033063, GO:0005657, GO:0005524, GO:0008094, GO:0140664, GO:0003677, GO:0043015, GO:0003697, GO:0006281, GO:0000724, GO:0036297, GO:0007131, GO:0051726, GO:0042148, GO:0000723, GO:0000722, IPR003593, IPR013632, IPR016467, IPR027417, IPR020588, O75771",3,8OUZ,wildtype,O75771,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,7
8P06,,,,,,8P06,"Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((2-(4H-1,2,4-triazol-4-yl)pyridin-4-yl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile","Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((2-(4H-1,2,4-triazol-4-yl)pyridin-4-yl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile",TRANSFERASE,CSNK2A1,,"GO:0005524, GO:0004674, GO:0006468, IPR045216, IPR011009, IPR000719, IPR017441, IPR008271",1,8P06,wildtype,Q5U5J2,UniProt,C17 H14 N10,358.36,WAU,"7-(cyclopropylamino)-5-[[2-(1,2,4-triazol-4-yl)pyridin-4-yl]amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile",c1cnc(cc1Nc2cc(n3c(n2)c(cn3)C#N)NC4CC4)n5cnnc5,3
8S91,,,,,,8S91,"Specificity, Activity, and Structure of the MCM8/9 Helicase",Structure of Walker B mutated MCM8/9 heterohexamer complex with ADP,DNA BINDING PROTEIN,"MCM8, C20orf154",3.6.4.12,"GO:0005694, GO:0042555, GO:0097362, GO:0005654, GO:0005634, GO:0005524, GO:0016887, GO:0003682, GO:0003678, GO:0019899, GO:0032406, GO:0032407, GO:0032408, GO:0003697, GO:0007049, GO:0006974, GO:0032508, GO:0000724, GO:0007292, GO:0048232, GO:0070716, GO:0071168, GO:0050821, GO:0036298, IPR003593, IPR031327, IPR001208, IPR041562, IPR033762, IPR012340, IPR027417, Q9UJA3",1,8S91,Mutant,Q9UJA3,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8S94,,,,,,8S94,"Specificity, Activity, and Structure of the MCM8/9 Helicase",Structure of C-terminal domains of Walker B mutated MCM8/9 heterohexamer complex with ADP,DNA BINDING PROTEIN,"MCM8, C20orf154",3.6.4.12,"GO:0005694, GO:0042555, GO:0097362, GO:0005654, GO:0005634, GO:0005524, GO:0016887, GO:0003682, GO:0003678, GO:0019899, GO:0032406, GO:0032407, GO:0032408, GO:0003697, GO:0007049, GO:0006974, GO:0032508, GO:0000724, GO:0007292, GO:0048232, GO:0070716, GO:0071168, GO:0050821, GO:0036298, IPR003593, IPR031327, IPR001208, IPR041562, IPR033762, IPR012340, IPR027417, Q9UJA3",1,8S94,Mutant,Q9UJA3,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8SZA,,,,,,8SZA,How NINJ1 mediates plasma membrane rupture and why NINJ2 cannot,Cryo-EM Structure of NINJ1 Filament at 2.75 Angstrom Resolution,MEMBRANE PROTEIN,NINJ1,,"GO:0005576, GO:0097060, GO:0098631, GO:0001530, GO:0140912, GO:0001525, GO:0007155, GO:0034113, GO:0006954, GO:0031640, GO:0002232, GO:0042692, GO:0007399, GO:0045766, GO:0050729, GO:0034145, GO:0012501, GO:0051260, GO:0090025, GO:0042246, IPR007007, Q92982, Generic PDBTM",1,8SZA,wildtype,Q92982,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,2
8SZB,,,,,,8SZB,How NINJ1 mediates plasma membrane rupture and why NINJ2 cannot,Cryo-EM Structure of NINJ2 Filament at 3.07 Angstrom Resolution,MEMBRANE PROTEIN,NINJ2,,"GO:0005886, GO:0007155, GO:0007399, GO:0007158, GO:0042246, IPR007007, Q9NZG7, Generic PDBTM",1,8SZB,wildtype,Q9NZG7,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,2
